AFP peptides after TACE

Phase 2

Recruiting

• Conditions: Hepatocellular carcinoma

• Registration Number: JPRN-jRCT2041220154
• Lead Sponsor: Mizukoshi Eishiro

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-03-02
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 84

Inclusion Criteria

1) clinically diagnosed as hepatocellular carcinoma
2) unsuitable for local therapy and treated by TACE
3) recoverd by adverse events due to TACE
4) HLA (Human Leukocyte Antigen) -A24
5) Child-Pugh classification A or B
6) 20 years or older
7) ECOG Performance status <=2
8) preservation of major organ function
9) written informed consent

Exclusion Criteria

1) refractory ascites or pleural effusion
2) encephalopathy within 3 months
3) risky varices
4) active double cancer
5) pregnant or lactating women, or women of childbearing potential
6) mental disorder
7) previously treated by AFP peptide or adjuvant
8) allergy for AFP peptide or adjuvant
9) previously treated by immunotherapy
10) allergy for contrast agents for CT and MRI
11) patients who investigator regards as inappropriate for candidate

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Relapse-free survival

Secondary Outcome Measures

Name	Time	Method
Immunological response, Adverse events, Overall survival